Replimune Group (NASDAQ:REPL – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05, Briefing.com reports. During the same period last year, the business earned ($0.78) earnings per share. Replimune Group Price Performance NASDAQ REPL traded up $0.54 during […]
Emerald Advisers LLC cut its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 18.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 963,041 shares of the company’s stock after selling 223,000 shares during the period. Emerald Advisers LLC […]
Emerald Mutual Fund Advisers Trust trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 16.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 803,448 shares of the company’s stock after selling 162,490 shares during the […]
Emerald Mutual Fund Advisers Trust lessened its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 16.8% during the 1st quarter, Holdings Channel reports. The firm owned 803,448 shares of the company’s stock after selling 162,490 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Replimune Group were worth $14,189,000 at the […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Pamela Esposito sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $21.58, for a total transaction of $431,600.00. Following the completion of the transaction, the insider now directly owns 263,436 […]